Aurinia [AUPH] vs Regeneron [REGN] Detailed Stock Comparison

Aurinia Pharmaceuticals Inc.

NASDAQ
Loading...

Regeneron Pharmaceuticals, Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Aurinia Pharmaceuticals Inc. wins in 9 metrics, Regeneron Pharmaceuticals, Inc. wins in 10 metrics, with 1 ties. Regeneron Pharmaceuticals, Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Aurinia Pharmaceuticals Inc. Regeneron Pharmaceuticals, Inc. Better
P/E Ratio (TTM) 7.80 18.00 Aurinia Pharmaceuticals Inc.
Price-to-Book Ratio 3.67 2.45 Regeneron Pharmaceuticals, Inc.
Debt-to-Equity Ratio 12.87 9.51 Regeneron Pharmaceuticals, Inc.
PEG Ratio 0.00 -4.80 Tie
EV/EBITDA 13.43 16.72 Aurinia Pharmaceuticals Inc.
Profit Margin (TTM) 101.47% 31.41% Aurinia Pharmaceuticals Inc.
Operating Margin (TTM) 55.68% 23.13% Aurinia Pharmaceuticals Inc.
EBITDA Margin (TTM) 55.68% 23.13% Aurinia Pharmaceuticals Inc.
Return on Equity 59.91% 14.86% Aurinia Pharmaceuticals Inc.
Return on Assets (TTM) 11.16% 5.91% Aurinia Pharmaceuticals Inc.
Free Cash Flow (TTM) $135.41M $3.77B Regeneron Pharmaceuticals, Inc.
Dividend Yield N/A 0.59% N/A
1-Year Return 93.40% 15.66% Aurinia Pharmaceuticals Inc.
Price-to-Sales Ratio (TTM) 7.41 5.50 Regeneron Pharmaceuticals, Inc.
Enterprise Value $1.82B $70.98B Regeneron Pharmaceuticals, Inc.
EV/Revenue Ratio 6.44 4.95 Regeneron Pharmaceuticals, Inc.
Gross Profit Margin (TTM) 88.59% 84.95% Aurinia Pharmaceuticals Inc.
Revenue per Share (TTM) $2 $137 Regeneron Pharmaceuticals, Inc.
Earnings per Share (Diluted) $2.07 $41.48 Regeneron Pharmaceuticals, Inc.
Beta (Stock Volatility) 1.52 0.40 Regeneron Pharmaceuticals, Inc.
Short % of Float 8.90% 2.55% Regeneron Pharmaceuticals, Inc.

Aurinia Pharmaceuticals Inc. vs Regeneron Pharmaceuticals, Inc. Stock Performance Analysis

Loading Price Chart...

AUPH
REGN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Aurinia Pharmaceuticals Inc.1.14%2.17%4.71%11.81%1.98%4.23%
Regeneron Pharmaceuticals, Inc.0.46%0.60%-11.93%-18.75%-18.29%-20.78%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Aurinia Pharmaceuticals Inc.93.40%64.28%21.69%510.81%324.13%324.13%
Regeneron Pharmaceuticals, Inc.15.66%-21.83%13.80%72.82%1,033.17%4,804.97%

Performance & Financial Health Analysis: Aurinia Pharmaceuticals Inc. vs Regeneron Pharmaceuticals, Inc.

MetricAUPHREGN
Market Information
Market Cap i$2.08B$80.98B
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i941,419642,495
90 Day Avg. Volume i1,107,942617,765
Last Close$16.00$614.98
52 Week Range$7.28 - $16.88$503.25 - $821.11
% from 52W High-5.21%-25.10%
All-Time High$33.97 (Nov 01, 2021)$1,211.20 (Aug 26, 2024)
% from All-Time High-52.90%-49.23%
Growth Metrics
Quarterly Revenue Growth0.29%0.03%
Quarterly Earnings Growth146.51%-0.08%
Financial Health
Profit Margin (TTM) i1.01%0.31%
Operating Margin (TTM) i0.56%0.23%
Return on Equity (TTM) i0.60%0.15%
Debt to Equity (MRQ) i12.879.51
Cash & Liquidity
Book Value per Share (MRQ)$4.39$304.65
Cash per Share (MRQ)$2.99$83.86
Operating Cash Flow (TTM) i$135.66M$4.98B
Levered Free Cash Flow (TTM) i$91.41M$3.26B
Dividends
Last 12-Month Dividend Yield iN/A0.59%
Last 12-Month Dividend iN/A$4.46

Valuation & Enterprise Metrics Analysis: Aurinia Pharmaceuticals Inc. vs Regeneron Pharmaceuticals, Inc.

MetricAUPH (Apr 26, 2026)REGN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i7.8018.00
Forward P/E i19.6814.21
PEG Ratio i0.00-4.80
Price to Sales (TTM) i7.415.50
Price to Book (MRQ) i3.672.45
Market Capitalization
Market Capitalization i$2.08B$80.98B
Enterprise Value i$1.82B$70.98B
Enterprise Value Metrics
Enterprise to Revenue i6.444.95
Enterprise to EBITDA i13.4316.72
Risk & Other Metrics
Beta i1.520.40
Book Value per Share (MRQ) i$4.39$304.65

Financial Statements Comparison: Aurinia Pharmaceuticals Inc. vs Regeneron Pharmaceuticals, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricAUPH (2025)REGN (2025)
Revenue/Sales i283.06M14.34B
Cost of Goods Sold i32.67M2.10B
COGS % of Revenue i11.5%14.6%
Gross Profit i250.39M12.24B
Gross Margin i88.5%85.4%
Research & Development i32.51M5.85B
Operating Income (EBIT) i106.56M3.70B
Operating Margin i37.6%25.8%
EBITDA i139.58M5.00B
EBITDA Margin i49.3%34.8%
Pre-Tax Income i114.16M5.23B
Pre-Tax Income % of Revenue i40.3%36.5%
Income Tax i-173.05M725.80M
Income Tax % of Revenue i-61.1%5.1%
Net Income (Profit) i287.20M4.50B
Profit Margin i101.5%31.4%

Balance Sheet & Liquidity Metrics

MetricAUPH (2025)REGN (2025)
Cash & Equivalents i80.21M3.12B
Total Current Assets i491.97M18.02B
Total Current Assets % of Revenue i173.8%125.7%
Total Current Liabilities i93.72M4.37B
Total Current Liabilities % of Revenue i33.1%30.5%
Long-Term Debt i57.22M2.71B
Long-Term Debt % of Revenue i20.2%18.9%
Total Shareholders Equity i581.33M31.26B
Retained Earnings i-649.37M35.80B
Retained Earnings % of Revenue i-229.4%249.6%
Property, Plant & Equipment i77.46M1.54B

Cash Flow Statement Comparison

MetricAUPH (2025)REGN (2025)
Operating Cash Flow i135.29M6.30B
Operating Cash Flow % of Revenue i47.8%43.9%
Capital Expenditures i-252,0000
Free Cash Flow i135.41M3.77B
FCF Margin i47.8%26.3%
Debt Repayment i-13.14MN/A
Common Stock Repurchase i-98.16M-3.97B

Short Interest & Institutional Ownership Analysis

MetricAUPHREGN
Shares Short i10.81M2.55M
Short Ratio i8.994.46
Short % of Float i8.90%2.55%
Shares Outstanding i132.32M105.72M
Float Shares i130.61M98.55M
% Held by Insiders i7.36%1.98%
% Held by Institutions i57.26%91.08%
% Held by Public i35.38%6.94%

Dividend Analysis & Yield Comparison: Aurinia Pharmaceuticals Inc. vs Regeneron Pharmaceuticals, Inc.

MetricAUPHREGN
Last 12-Month Dividend iN/A$4.46
Last 12-Month Dividend Yield iN/A0.59%
3-Year Avg Annual Dividend iN/A$1.49
3-Year Avg Dividend Yield iN/A0.13%
3-Year Total Dividends iN/A$4.46
Ex-Dividend DateN/AFeb 20, 2026